TP53 nel tumore al seno: studi, trial e ricerca
MBC INTELLIGENCE SEARCH · KNOWLEDGE GRAPH PUBBLICO
TP53 nel tumore al seno
Pagina documentale costruita esclusivamente da fonti, record e relazioni presenti nel Knowledge Graph MBC. Non formula raccomandazioni terapeutiche.
Copertura documentale
Il Quality Gate pubblico registra 14 supporti documentali, 4 fonti indipendenti e 6 relazioni. Questi valori misurano documentazione e provenienza, non efficacia o appropriatezza clinica.
Documenti indicizzati collegati
- TP53 mutations predict poor breast cancer–specific survival in ER-positive breast cancer patients — Crossref
- Exploring the Anticancer Potential of Some Selected Medicinal Plants from Amroha District against Human Breast Cancer (MCF-7) Cells and Cervical Carcinoma (HeLa) Cells — Crossref
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — ClinicalTrials.gov
- Genomic and transcriptomic landscape of overweight Chinese breast cancer reveals NOTCH2 mutation–mediated endocrine resistance and therapeutic strategies — Crossref
- Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial. — Europe PMC
- Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival — Crossref
- Comprehensive Genomic Profiling Reveals the Mutational Spectrum and Clinical Significance of BRCA1/2 and Other Cancer-Susceptibility Genes in Breast Cancer Patients from Southern Tunisia — Crossref
- Subtype-specific ZMYND10 expression as a potential novel prognostic and treatment marker for ER-positive/HER2-negative breast cancer — Crossref
- A Pan-Cancer Single-Cell Analysis of Intratumoral Copy-Number Diversity and Evolution — Crossref
- Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer — ClinicalTrials.gov
- Multi-target drug discovery of Sclerocarya birrea bioactive moieties against drug resistance in triple-negative breast cancer (TNBC) targeting BCL2, CASP3, and JUN modulation; a polypharmacological and molecular modelling approach — Crossref
- Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer — Crossref
Collegamenti nel Knowledge Graph
Come interpretare questa pagina
Una relazione documentale non equivale a una raccomandazione. Risultati favorevoli nelle condizioni studiate, non favorevoli nelle condizioni studiate, non concordanti o con dati insufficienti restano consultabili nel motore con la loro provenienza.
Privacy
Questa pagina deriva esclusivamente dal patrimonio scientifico pubblico indicizzato. Il Publisher non usa IP, cookie, account, cronologia, fingerprint o ricerche individuali.
Quality Gate documentale: 92/100 · ultimo aggiornamento Settembre 29, 2026